New stock news | Anker Yoda submitted the Hong Kong Stock Exchange CNV-seq test kit for the third time and obtained three types of medical device certificates.

According to the disclosure by the Hong Kong Stock Exchange on April 15th, Annor Opta Genomics Technology (Beijing) Co., Ltd. (referred to as Annor Opta) has submitted its third listing application to the main board of the Hong Kong Stock Exchange, with Build International and Guotai Haitong as its joint sponsors. Company Overview According to the prospectus, the company is focused on molecular diagnostics-based IVD medical devices and multi-omics life science research services. The company is committed to promoting clinical diagnostics and advancing life science research through integrated life science sequencing solutions. The company's clinical sequencing solutions include self-produced IVD test kits based on genetic sequencing, genetic sequencers, bioinformatics analysis software, as well as support technology and laboratory design services. The IVD test kits mainly include the NIPT test kit for fetal genetic abnormalities detection and the CNV-seq test kit. The company's NIPT test kit obtained Class III medical device certification in 2017, making it one of the few companies in China to achieve this milestone. The company further developed the CNV-seq test kit and obtained Class III medical device certification in 2024. In addition, the company's self-developed NextSeq550AR sequencer, when used in conjunction with the company's test kits and bioinformatics software, creates a synergistic effect. This is because hospitals and independent medical laboratory customers typically prefer life science sequencing solution providers with a comprehensive IVD product portfolio, and prefer IVD test kits that are compatible with their existing sequencers. Furthermore, the company provides integrated research sequencing solutions for reputable academic and research institutions, including single-cell and spatial sequencing, de novo sequencing, resequencing, transcriptome regulation sequencing, microbial sequencing, and customized sequencing. As of December 31, 2025, the company has a research and development team consisting of 66 professionals with relevant research and development experience in genetics and bioinformatics, including ten Ph.D. holders and 39 Master's degree holders. The company plans to continue developing IVD products based on its existing platform and introduce innovative sequencing technologies for research sequencing solutions. The company plans to increase the market penetration of its existing IVD products. During the historical period, the company sold 7,038, 8,979, and 9,724 NIPT test kits to 61, 79, and 98 hospitals in 2023, 2024, and 2025, respectively, as well as 13, 13, and 14 independent medical laboratories. As of December 31, 2025, the company sold 485 CNV-seq test kits to 40 customers, of which 27 customers were also NIPT customers of the company, demonstrating the synergistic effect of the company's different IVD test kits. The company is expanding into the Alzheimer's disease testing market and launching new AD test kits. Financial Information Revenue In 2023, 2024, and 2025, the company's revenues were approximately RMB 475 million, RMB 518 million, and RMB 547 million, respectively. Loss In 2023, 2024, and 2025, the company's annual losses were approximately RMB 240 million, RMB 126 million, and RMB 54.399 million, respectively. Research and Development In 2023, 2024, and 2025, the company's research and development costs were RMB 44.93 million, RMB 26.598 million, and RMB 42.737 million, respectively. Industry Overview The Chinese life science sequencing solutions market can be further divided into the clinical sequencing field (including reproductive health sequencing solutions market, tumor sequencing, and pathogen detection) and the research sequencing field. According to industry data from 2018 to 2024, calculated by end-user prices, the market size of life science sequencing solutions increased from RMB 13.2 billion to RMB 28.5 billion, with a compound annual growth rate of 13.7%. It is expected that by 2033, the market size will grow at a compound annual growth rate of 18.2% to reach RMB 128.7 billion. According to data from the National Bureau of Statistics, China's annual birth rate decreased from 1.1% in 2018 to 0.6% in 2023, and increased to 0.7% in 2024. It is estimated that by 2033, China's population birth rate will stabilize at a ratio of 6.41 per 1,000 people. At the same time, the number of NIPT tests conducted in China increased from approximately 2.7 million in 2018 to approximately 5.6 million in 2024, with a compound annual growth rate of 13.2%. During the same period, the penetration rate of NIPT in pregnant women in China increased from approximately 15.4% in 2018 to approximately 54.5% in 2024, indicating significant growth and a huge remaining market penetration space. In terms of patient expenditure, the Chinese NIPT market size has increased from RMB 4.7 billion in 2018 to RMB 9.9 billion in 2024, with a compound annual growth rate of 13.1%. It is expected that the market size will further increase at a compound annual growth rate of 6.5%, reaching RMB 17.4 billion by 2033. Patient expenditure refers to the out-of-pocket expenses of terminal patients in NIPT services. In January 2024, China's first chromosomal aneuploidy and gene micro-deletion test kit received approval from the National Medical Products Administration, providing a compliant IVD solution for CNV-seq. It is expected that from 2024 onwards, the CNV-seq test kit will cover more medical institutions and provide services to more high-risk pregnant women. The market size of CNV-seq calculated by patient expenditure is expected to grow rapidly and reach RMB 417 million by 2028, and RMB 1.9 billion by 2033. Patient expenditure refers to the expenditure of terminal patients on CNV-seq services. Board Information The company's board of directors consists of nine directors, including three executive directors, three non-executive directors, and three independent non-executive directors. Directors serve for a term of three years and can be re-elected. Equity Structure As of the last practicable date (April 7, 2026), the company is directly held by Mr. Xia, Annor Brilliant, Shi Fenghuafu, and Zhengxuan Annor, holding 9.95%, 4.75%, 20.74%, and 18.82% stakes, respectively. Annor Brilliant's general partner is Shenzhen Zhengxuan, and Shenzhen Zhengxuan is wholly owned by Mr. Xia with 97.25% equity. Shi Fenghuafu's general partner is Ningbo Meidixin, and Ningbo Meidixin is fully owned by Shenzhen Zhengxuan. On October 21, 2021, Zhengxuan Annor and Mr. Xia entered into a consistent action agreement, under which they agreed to vote consistently when exercising their voting rights in the company. If there are any differences between Zhengxuan Annor and Mr. Xia, Mr. Xia's decision will prevail. As of the last practicable date, Mr. Xia has the right to control 54.25% of the company's voting rights. Therefore, Mr. Xia, Shi Fenghuafu, Annor Brilliant, Zhengxuan Annor, Ningbo Meidixin, and Shenzhen Zhengxuan constitute the controlling shareholder group. Advisory Team Joint Sponsors: Build International Financial Limited, Guotai Junan Financing Limited; Auditors and Reporting Accountants: Ernst & Young LLP; Legal Advisors: Gallant Legal Firm, King & Wood Mallesons Law Firm; Joint Sponsors and Co-editing Legal Advisers: Tianyuan Law Firm (Limited Partnership), Haiwen Law Firm; Industry Consultants: Zhaoshi Consulting; Compliance Consultants: CMBC CAPITAL Limited.